- Home
- Publications
- Publication Search
- Publication Details
Title
Immune modulation for treatment of allergic disease
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume 242, Issue 1, Pages 258-271
Publisher
Wiley
Online
2011-06-20
DOI
10.1111/j.1600-065x.2011.01034.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Th2 Cytokine Inhibitor Suplatast Tosilate Inhibits Antigen-Induced Mucus Hypersecretion in the Nasal Epithelium of Sensitized Rats
- (2014) Shino Shimizu et al. ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY
- A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
- (2010) Jonathan Corren et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males
- (2010) Chad K. Oh et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children
- (2010) M. Rosewich et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Sublingual Allergen-Specific Immunotherapy Adjuvanted with Monophosphoryl Lipid A: A Phase I/IIa Study
- (2010) Oliver Pfaar et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- Effects of Rosiglitazone on Airway Hyperresponsiveness and Obstruction in Asthma
- (2010) M.S. Sandhu et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
- (2010) William W. Busse et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
- (2010) Roland Kolbeck et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
- (2010) Marc Massanari et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Churg-Strauss Syndrome in Patients Treated With Omalizumab
- (2009) Michael E. Wechsler et al. CHEST
- Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial
- (2009) G. Senti et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Bronchodilatory Effect of the PPAR-γ Agonist Rosiglitazone in Smokers With Asthma
- (2009) M Spears et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
- (2009) A Straumann et al. GUT
- Suplatast Tosilate Inhibits Histamine Signaling by Direct and Indirect Down-Regulation of Histamine H1 Receptor Gene Expression through Suppression of Histidine Decarboxylase and IL-4 Gene Transcriptions
- (2009) M. Shahriar et al. JOURNAL OF IMMUNOLOGY
- Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
- (2009) Pranabashis Haldar et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia
- (2009) Parameswaran Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Suplatast Tosilate on Antileukotriene Non-Responders with Mild-to-Moderate Persistent Asthma
- (2009) Mariko Wada et al. ALLERGOLOGY INTERNATIONAL
- Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment
- (2008) E. L. J. van Rensen et al. ALLERGY
- Antisense Therapy against CCR3 and the Common Beta Chain Attenuates Allergen-induced Eosinophilic Responses
- (2008) Gail M. Gauvreau et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Peroxisome Proliferator-Activated Receptors as Novel Targets in Lung Disease*
- (2008) Maria G. Belvisi CHEST
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started